Literature DB >> 2458700

Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose gamma-globulin intravenously.

B W Boom1, A Brand, J N Bavinck, J G Eernisse, M R Daha, B J Vermeer.   

Abstract

We describe a patient with long-standing severe leukocytoclastic vasculitis of the skin and essential mixed cryoglobulinemia type II, who showed a limited reaction to immunosuppressive drugs, plasmapheresis, and colchicine. Therapy with high-dose gamma-globulin intravenously (IV) for five days resulted in disappearance of vasculitis lesions within three weeks. After gamma-globulin IV treatment there was a decrease in cryoglobulin, circulating immune complexes, and IgM, paraprotein, and a rise in complement levels. No serious side effects were noted during or after gamma-globulin IV treatment. The patient has been in remission for 16 months.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458700

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  5 in total

Review 1.  Treatment of vasculitis.

Authors:  H G Taylor; A Samanta
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

2.  Deposits of paraprotein in small vessels as a cause of skin ulcers in Waldenström's macroglobulinemia.

Authors:  D R Wagner; F Eckert; U Gresser; M Landthaler; M Middeke; N Zöllner
Journal:  Clin Investig       Date:  1993-12

Review 3.  Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders.

Authors:  Andreas Steinbrecher; Peter Berlit
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

4.  Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin.

Authors:  Y Kuroda; H Takashima; A Ikeda; C Endo; R Neshige; R Kakigi; H Shibasaki
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

Review 5.  Symptomatic cryoglobulinemia.

Authors:  A Dispenzieri
Journal:  Curr Treat Options Oncol       Date:  2000-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.